The wait for the World Health Organisation (WHO)’s emergency use authorisation (EUA) for Hyderabad-based Bharat Biotech’s COVID-19 vaccine Covaxin is set to be a little longer as the global health body is said to have delayed the approval till 5 October, reports Hindustan Times.
WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) will be meeting on 5 October to decide on granting the EUA to Covaxin. It will be analysing the data from the vaccine’s first, second and third stage clinical trials.
The SAGE will also be considering post-marketing studies on safety, immunogenicity, efficacy, and effectiveness. It will also review updates on global, regional, and country-level plans for vaccine safety monitoring.
It should be noted that Covaxin is the first indigenously developed COVID-19 vaccine in India. It was developed by Dr Krishna Ella led Bharat Biotech in close collaboration with the Indian Council for Medical Research (ICMR) and the Pune-based National Institute of Virology.
Covaxin is presently the second-most administered COVID-19 vaccine in India after Covishield which is being manufactured by the Pune-based Serum Institute of India (SII). The Covishield has been developed by Swedish-British pharmaceutical major AstraZeneca and the University of Oxford.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.